59 results about "Chronic renal insufficiency" patented technology

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression/encapsulation aids; disintegrants; lubricants; plasticizers; slip/anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm³ and 1.2 cm³, preferably between 0.35 cm³ and 0.50 cm³. Each tablet typically includes enough phosphate binder such that only 3 or less tablets need to be ingested each day for a patient suffering from ESRD.

The invention discloses a compound alpha-keto acid dispersible tablet for treating chronic kidney diseases, containing four kinds of keto amino acid calcium, one kind of hydroxyamino acid calcium, five kinds of amino acid and pharmaceutically acceptable adjuvants. The tablet is mainly and clinically used for postponing renal failure process, correcting metabolic disturbance, coordinating with low-protein diet and preventing and treating damages caused by protein metabolism disorder because of chronic renal insufficiency.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune/inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

The present invention discloses a Chinese medicine for effectively curing chronic nephrosis with obvious therapeutic effect. Said Chinese medicine is made up by using 12 Chinese medicinal materials of cooked rehmannia root, Chinese yam, moutan root bark, alisma tuber, poria, hedyotis and others through a certain preparation process. Said Chinese medicine has the functions of improving renal function, regulating lipometabolism, reducing urinary protein and raising immunity of body, so that it can be effectively used for curing the diseases of chronic renal insufficiency and renal failure, etc.

The invention discloses a medicine for treating chronic renal insufficiency and chronic renal failure diseases. The medicine comprises the following raw materials in parts by weight: 70-90 parts of hairy antler, 17-23 parts of prepared common monkshood daughter root, 70-90 parts of cassia twig and 170-230 parts of all-grass of desertliving cistanche; preferably, the medicine also comprises the following raw materials in parts by weight: 170-230 parts of common macrocarpium fruit, 85-115 parts of prepared rhizome of rehmannia, 170-230 parts of largehead atractylodes rhizome, 170-230 parts of Chinese angelica and 45-55 parts of astragalus membranaceus; preferably, the medicine also comprises the following raw materials in parts by weight: 170-230 parts of Indian buead, 170-230 parts of plantain seed and 17-23 parts of root-bark of tree peony; and preferably, the medicine also comprises the following raw materials in parts by weight: 85-115 parts of twotooth achyranthes root and 45-55 parts of rheum rhabarbarum. The medicine disclosed by the invention can be used for tonifying the kidney-qi, strengthening the kidney-yang and recovering the renal functions, and can be used for treating chronic renal insufficiency, chronic renal failure, limb weakness, waist-knee-limb coldness, difficult urination, frequent urination or nighttime micturition, bleak or dark complexion, sluggish in facial expression, double-limb pitting edema, face and eye edema, urea nitrogen increase, creatinine increase, hypertensive nephropathy and diabetic nephropathy caused by insufficiency of kidney-yang, and treating the chronic renal insufficiency and chronic renal failure diseases caused by medicine injury or other reasons.

(S)-(−)-5-hydroxy-1-methylhydantoin is useful as a drug having high safety. Since the compound of the present invention, (S)-(−)-5-hydroxy-1-methylhydantoin, rarely changes to the metabolite having high toxicity compared with the R-form and the racemate, it is preferred as an agent for renal failure especially when used for chronic renal insufficiency in a patient where toxic substances are not excreted, but are accumulated in the body due to disturbance of renal functions.

The invention discloses a type of polyethylene glycol erythropoietin, which is prepared from non-glycosylated rhEPO(rhngEPO) or point mutant thereof, and N-terminal amino of single and single chain PEG molecule having molecular weight greater than 20kDa or mercapto of cysteine mutational state by fixed point coupling, wherein the olyethylene glycol erythropoietin has the molecular structural formula of CH3-(CH2CH2-O)n-(CH2)r-NH-rhngEPO or CH3-(CH2CH2-O)n-X-S-rhngEPOm, wherein n is 100 to 2,200, r is 0 to 4, and X is S or C. The PEG-rhngEPO or PEG-rhEPOm molecule simultaneously has long-acting preparation characteristics such as long acting, high efficiency and low immunogenicity, and establishes foundation for preparing parent long-acting preparation for treating anemia caused by chronic renal insufficiency, tumor, anemia caused by AIDS chemotherapy, marrow brain nerve damage, and selective operation auto-transfusion.

The invention discloses a Chinese medicinal formulation for treating chronic renal insufficiency, which is prepared from Chinese medicinal herbs including American ginseng, hairy deerhorn, white atractylodes rhizome, Poria cocos, amomum fruit, Cinnamomum cassia, lepidium seed, talcum powder, Ligusticum wallichii, cuttlebone through rouging, frying, washing, mixing and disintegrating, sieving, split charging, and disinfecting.

The invention relates to use of cordyceps cicadae in preparation of drugs for preventing or treating gout. According to the use, due to cordyceps cicada preparation products, a novel gout preventing or treating method is provided and is obvious in effect. The cordyceps cicadae have the functions of reducing blood and urine creatinine, increasing endogenous creatinine clearance rate, increasing the content of serum protein, reducing the discharge of urinary protein, and the like. Therefore, the cordyceps cicadae have definite treatment effect on early- and middle-stage chronic renal insufficiency patients. Confirmed by further researches: the cordyceps cicadae have relatively good treatment effect on renal tubulointerstitial lesions and can be used for protecting Na<+>-K<+>-ATPase of renal tubule cells, alleviating cytolysosome and cell lipid peroxidation injury, improving renal hemodynamics and alleviating endothelial cell injury and blood coagulation property.

The present invention discloses a Chinese medicine for curing chronic nephritis and chronic renal insufficiency with obvious therapeutic effect and small size effect. Said invention is made up by using 7 Chinese medicinal materials of centella, cornus fruit, ligusticum root, astragalus root, salvia root and others.

The invention relates to a medical instrument for nephrology department. The medical instrument comprises a tube body, a guide supporting rod and a supporting frame tube, wherein the guide supporting rod is fixedly arranged at an upper end of the tube body, the guide supporting rod is movably arranged in the supporting frame tube, a limiting assembly is arranged outside the tube body, and the limiting assembly is used for limiting and guiding the tube body. By improving existing equipment for treating chronic renal insufficiency, the improved equipment for treating chronic renal insufficiency can realize an adjustable performance of a heating contact, so that in an actual use process, the adjustable performance of the heating contact can be realized, medicaments can be added to different parts of the intestinal tract, and a traditional Chinese medicine decoction at different parts can be heated through the medical instrument, so that the traditional Chinese medicine decoction can be better absorbed.

A Chinese medicine for treating chronic renal insufficiency is prepared from 14 Chinese-medicinal materials including red sage root, astragalus root, red peony root, rhubarb, etc through respectively pre-treating and proportional dispensing.

A Chinese medicine for treating chronic renal interstitial fibrosis and chronic renal insufficiency is prepared from 10 Chinese-medicinal materials including red sage root, astragalus root, Chinese angelica root, notoginseng, etc. Its preparing process is also disclosed.